BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qin C, Song Y, Liu X, Gai Y, Liu Q, Ruan W, Liu F, Hu F, Lan X. Increased uptake of 68Ga-DOTA-FAPI-04 in bones and joints: metastases and beyond. Eur J Nucl Med Mol Imaging 2021. [PMID: 34241652 DOI: 10.1007/s00259-021-05472-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Hotta M, Rieger AC, Jafarvand MG, Menon N, Farolfi A, Benz MR, Calais J. Non-oncologic incidental uptake on FAPI PET/CT imaging. Br J Radiol 2023;96:20220463. [PMID: 35776566 DOI: 10.1259/bjr.20220463] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
2 Kirienko M, Erba PA, Chiti A, Sollini M. Hybrid PET/MRI in Infection and Inflammation: An Update About the Latest Available Literature Evidence. Semin Nucl Med 2023;53:107-24. [PMID: 36369091 DOI: 10.1053/j.semnuclmed.2022.10.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Li Y, Deng L, Feng Y, Chen Y, Lv F, Qiu L. Potential utility of 68Ga-DOTA-FAPI-04 as a broad-spectrum benign disease imaging agent—comparison with 18F-FDG and 99mTc-MDP.. [DOI: 10.21203/rs.3.rs-2368208/v1] [Reference Citation Analysis]
4 Glatting FM, Hoppner J, Liew DP, van Genabith A, Spektor AM, Steinbach L, Hubert A, Kratochwil C, Giesel FL, Dendl K, Rathke H, Kauczor HU, Huber PE, Haberkorn U, Röhrich M. Repetitive Early (68)Ga-FAPI PET Acquisition Comparing (68)Ga-FAPI-02, (68)Ga-FAPI-46, and (68)Ga-FAPI-74: Methodologic and Diagnostic Implications for Malignant, Inflammatory/Reactive, and Degenerative Lesions. J Nucl Med 2022;63:1844-51. [PMID: 35618480 DOI: 10.2967/jnumed.122.264069] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Schmidkonz C, Kuwert T, Atzinger A, Cordes M, Schett G, Ramming A, Götz T. Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging. J Nucl Med 2022;63:1786-92. [PMID: 36109182 DOI: 10.2967/jnumed.122.264205] [Reference Citation Analysis]
6 Qi N, Wang H, Wang H, Ren S, You Z, Chen X, Guan Y, Xie F, Hua F, Zhao J. Non-tumoral uptake of 68Ga-FAPI-04 PET: A retrospective study. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.989595] [Reference Citation Analysis]
7 Ruan W, Qin C, Liu F, Pi R, Gai Y, Liu Q, Lan X. Q.Clear Reconstruction for Reducing the Scanning Time for 68Gallium-DOTA-FAPI-04 PET/MR Imaging.. [DOI: 10.21203/rs.3.rs-2214028/v1] [Reference Citation Analysis]
8 Wu C, Zhang X, Zeng Y, Wu R, Ding L, Xia Y, Chen Z, Zhang X, Wang X. [18F]FAPI-42 PET/CT versus [18F]FDG PET/CT for imaging of recurrent or metastatic gastrointestinal stromal tumors. Eur J Nucl Med Mol Imaging 2022. [PMID: 36040490 DOI: 10.1007/s00259-022-05955-x] [Reference Citation Analysis]
9 Dondi F, Albano D, Treglia G, Bertagna F. Emerging Role of FAPI PET Imaging for the Assessment of Benign Bone and Joint Diseases. JCM 2022;11:4514. [DOI: 10.3390/jcm11154514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Wang Y, Li Y, Han L, Wang J, Zhang C, Qi E, Zhang D, Zhang X, Huan Y, Tian J. 18F-FDG and 68 Ga-FAPI PET/CT for the evaluation of periprosthetic joint infection and aseptic loosening in rabbit models. BMC Musculoskelet Disord 2022;23:592. [PMID: 35725436 DOI: 10.1186/s12891-022-05537-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Dong A, Yang Q, Hua M, Cheng C, Zuo C. Lipid-Poor Renal Angiomyolipoma Mimicking Renal Cell Carcinoma on 68Ga-FAPI-04 PET/CT. Clin Nucl Med 2022. [PMID: 35619202 DOI: 10.1097/RLU.0000000000004297] [Reference Citation Analysis]
12 Kou Y, Jiang X, Yao Y, Shen J, Jiang X, Chen S, Lu H, Wang X, Zhao M, Xiao D, Shen T, Zhang W, Cheng Z. Physiological tracer distribution and benign lesion incidental uptake of Al18F-NOTA-FAPI-04 on PET/CT imaging. Nucl Med Commun 2022. [PMID: 35506283 DOI: 10.1097/MNM.0000000000001563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Verhulst E, Garnier D, De Meester I, Bauvois B. Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go? Cancers (Basel) 2022;14:624. [PMID: 35158891 DOI: 10.3390/cancers14030624] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Treglia G, Muoio B, Roustaei H, Kiamanesh Z, Aryana K, Sadeghi R. Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [18F]F-FDG in Oncology: A Systematic Review. Int J Mol Sci 2021;22:11192. [PMID: 34681850 DOI: 10.3390/ijms222011192] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]